Nanoplastics, mRNA Therapy, & Drug Approvals | Longevity News Roundup — Week 9, 2026

In this week’s Longevity News Roundup, Phil Newman and Dr. Nina Patrick explore the latest discoveries transforming longevity science. From invisible nanoplastics crossing the blood-brain barrier to first-of-its-kind Klothea mRNA human trials, wearable lactate sensors, and AI models targeting aging-linked inflammation, this episode connects science, innovation, and real-world impact.Recent research shows that nanoplastics, ultra-small fragments of degraded plastic closer in size to viruses than visible debris, are accumulating in human brain tissue. Age does not predict accumulation, and higher concentrations appear in tissues affected by Alzheimer’s and vascular dementia. Klothea has launched a phase 1b human trial for their AKL003 mRNA therapy, aiming to boost levels of the longevity-associated protein alpha-Klotho. Conducted in Prospera, Honduras, the study measures epigenetic clocks, inflammatory and metabolic markers, mitochondrial function, sleep, and patient-reported quality of life. This represents one of the first human longevity trials designed around lifespan as the primary endpoint rather than disease. In sports and metabolic monitoring, PointFit is developing a wearable sweat patch that continuously tracks lactate, cortisol, creatine, and glucose. Lactate serves as a real-time biomarker for exercise intensity and fatigue, bridging elite athlete optimization and general population healthspan. Early adoption is expected in high-performance sports, but applications in rehab and clinical aging are promising.Regulatory innovation continues with the FDA officially ending the “two trial dogma.” One pivotal, rigorously designed trial may now suffice for drug approval, lowering barriers for therapies targeting aging processes and biomarker-driven endpoints. This shift could shave three to five years off development timelines and reduce costs by tens of millions, accelerating the path for human longevity drugs.Finally, AI is moving from broad discovery to targeted intervention. Scienta Lab unveiled EVA, a multimodal AI platform mapping inflammatory networks tied to aging, aiming to design precision anti-inflammatory therapies. Rather than simply accelerating existing pharma pipelines, platforms like EVA could guide the development of highly personalized interventions tailored to an individual’s inflammatory signature, tissue context, and age.The Longevity Show has confirmed Hertility as Strategic Content and Scientific Lead Partner for the Women’s Health Summit at its inaugural 2026 event in London. Hertility will co-lead the scientific framing and programme development of the Summit. The partnership positions female biology not as a thematic sidebar, but as a structural lens through which longevity science and infrastructure must increasingly be designed.______________________News & References:Nanoplastics found in the brain raise new aging questions → https://longevity.technology/news/nanoplastics-found-in-the-brain-raise-new-aging-questions/Klothea initiates longevity-focused human trial of klotho therapy → https://longevity.technology/news/klothea-initiates-longevity-focused-human-trial-of-klotho-therapy/Seveno backs PointFit wearable patch → https://longevity.technology/news/seveno-backs-pointfit-wearable-patch/FDA rewrites drug approval rules and longevity stands to gain → https://longevity.technology/news/fda-rewrites-drug-approval-rules-and-longevity-stands-to-gain/Scienta’s new AI model targets aging-linked inflammation → https://longevity.technology/news/scientas-new-ai-model-targets-aging-linked-inflammation/Hertility announced as Women’s Health Partner for Longevity Show → https://longevity.technology/news/hertility-announced-as-womens-health-partner-for-longevity-show/______________________Hosts:Phil Newman: ⁠⁠https://qrco.de/bgXpNY⁠⁠Nina Patrick: ⁠⁠https://qrco.de/bgXpKn⁠⁠